AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM
* New CVRM sales growth in Emerging Markets of 26% (40% at CER) to $239m
Total CVRM sales, which include Crestor and other legacy medicines, increased by 4% (9% at CER) to $1,714m.
The creation of the BioPharmaceuticals commercial unit aligns product strategy and commercial delivery across CVRM
Highlights also include data on the potential of Farxiga in type-1 diabetes (T1D) and additional pre-clinical and clinical data for MEDI0382, a potential first-in-class oxyntomodulin-like peptide for type-2 diabetes and the latest candidate in the Companys CVRM
Our ambition is to modify or halt the natural course of CVRM
diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.
AstraZeneca and its global biologics research and development arm, MedImmune, will present 45 abstracts including seven late-breaking data disclosures from the company's Cardiovascular, Renal and Metabolism, or CVRM
, therapy area at the American Diabetes Association's, or ADA.
About AstraZeneca in CV, renal and metabolism (CVRM
AstraZeneca focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in the three therapy areas of Oncology, CVRM
About AstraZeneca in CV, Renal & Metabolism (CVRM
These changes will include the creation of therapy area-focused Research and Development units that are responsible for discovery through to late-stage development, one for BioPharmaceuticals (Cardiovascular, Renal & Metabolism (CVRM
) and Respiratory) and one for Oncology, with dynamic resource allocation across the company's pipeline.
sales, which included Crestor and other legacy medicines, declined by 8% to $6,710m.